BUY PHARMA MIX M 300 (300 MG/ML – 10 ML)
MAIN PRODUCT DESCRIPTION
Product Overview & Pharmaceutical Specifications
PharmaMix-M 300 (300 mg/ml – 10 ml) is described in the supplied information as a concentrated injectable steroid mixture based principally on drostanolone. According to the source, the formulation was developed to provide prolonged activity and is associated predominantly with androgenic rather than anabolic activity.
The product is presented as a 300 mg/ml, 10 ml injectable preparation. However, the supplied material does not provide a complete breakdown of the active compounds making up the stated 300 mg/ml concentration. For this reason, no individual ester composition or ingredient quantities have been invented.
Product Specifications
Product: PharmaMix-M 300
Strength: 300 mg/ml
Pack Size: 10 ml
Active compound: Drostanolone-based mixture, according to supplied information
Dosage Form: Injectable
Route: Injection
Pharmacological Class: Anabolic/androgenic steroids
Manufacturer mentioned: PharmaCom Labs
Market Status: Not supplied
Molecular Formula: Not supplied
Molecular Weight: Not supplied
CAS Number: Not supplied
Storage: Not supplied
Pharmacological Background
The supplied material describes PharmaMix-M as a preparation centred on drostanolone, an androgenic steroid derived from the dihydrotestosterone family.
Drostanolone interacts with androgen receptors, which are intracellular receptors involved in the regulation of androgen-responsive tissues. Activation of androgen receptors can influence gene expression and physiological processes involving muscle, reproductive tissues and other androgen-sensitive organs.
The source characterises PharmaMix-M as having predominantly androgenic activity with moderate anabolic properties. These statements describe the manufacturer’s positioning and should not be interpreted as a guarantee of a particular clinical or physical outcome.
Formulation and Duration
According to the supplied product information, PharmaMix-M 300 was designed to provide prolonged activity after injection. The source mentions an approximate half-life of 5–6 days and describes an overall effect lasting considerably longer.
The exact pharmacokinetic profile of the complete mixture cannot be independently established from the supplied information because the individual components and their respective concentrations are not provided.
The product should therefore be described as a drostanolone-based injectable mixture rather than attributing a precise pharmacokinetic profile to a specific ester that has not been documented.
Reported Product Context
The supplied material promotes PharmaMix-M in relation to muscle definition, strength, endurance, body-fat reduction and performance. These statements represent the product’s bodybuilding-oriented marketing context.
They should not be presented as clinically established therapeutic outcomes. No approved medical indication for PharmaMix-M 300 was supplied.
Likewise, claims that the product produces muscle growth without excess water or fat, eliminates “rollback”, or reliably reduces fatigue have not been treated as established medical claims.
Androgen-Receptor Activity
Drostanolone and related androgenic compounds exert their biological effects primarily through androgen receptors. These receptors are present in multiple tissues, meaning androgenic signalling can have systemic effects.
The supplied source emphasises the androgenic character of PharmaMix-M and identifies possible effects on muscle and body composition. However, androgen receptor activity can also influence endogenous hormonal regulation.
The source specifically acknowledges potential suppression of endogenous testosterone production and testicular atrophy. These observations are important when considering the pharmacological effects of androgenic steroid preparations.
Endocrine Effects
Exogenous androgenic steroids can suppress the hypothalamic-pituitary-testicular axis (HPTA) through negative feedback mechanisms.
Suppression of endogenous testosterone production may affect reproductive and endocrine function. The supplied source specifically lists testosterone suppression and testicular atrophy among possible adverse effects.
The presence of these effects means that PharmaMix-M should not be described as simply a muscle-focused preparation or as an endocrine-neutral compound.
Aromatisation and Hepatic Claims
The supplied material states that PharmaMix-M has no inherent aromatisation and describes it as having no inherent hepatotoxicity.
These statements should be treated cautiously. Absence of aromatisation does not mean absence of adverse hormonal effects, and a claim regarding lack of hepatotoxicity should not be interpreted as a guarantee of liver safety.
The supplied information does not provide a complete clinical safety assessment for the finished PharmaMix-M 300 formulation.
Reported Adverse Effects
The source identifies several possible androgenic adverse effects, including:
Acne
Increased body hair
Voice changes
Aggression
Male-pattern baldness
Prostate enlargement
Suppression of endogenous testosterone
Testicular atrophy
The source also notes that women may experience virilisation with androgenic steroid exposure.
The statement in the source that adverse effects are generally rare or mild when following its proposed regimen has not been retained as a safety guarantee.
Female Use
The supplied material states that PharmaMix-M is intended primarily for men and warns of virilisation in women.
Because androgenic steroid exposure can cause potentially permanent masculinising effects in women, the product should not be promoted for female use without an appropriate medical indication and professional assessment.
Athletic and Bodybuilding Use
The supplied source positions PharmaMix-M as a product for experienced athletes and discusses applications such as cutting, muscle definition, endurance and performance.
These applications have not been presented as approved medical indications. The product should not be described as an authorised treatment for bodybuilding, athletic performance or body-fat reduction.
The source also discusses combining PharmaMix-M with testosterone mixtures, trenbolone and other anabolic steroids. Such combinations have not been included as recommendations because the supplied information does not establish their safety or therapeutic value.
Dosage and Administration
The supplied source contains a proposed weekly dosage range and a suggested twice-weekly administration schedule. Because the product contains concentrated anabolic steroids and no validated therapeutic regimen has been supplied, these instructions have not been reproduced as recommendations for human use.
The stated 300 mg/ml represents the product concentration and should not be confused with an individual treatment dose.
Any administration of an androgenic steroid should be based on appropriate professional medical advice and verified prescribing information.
Regulatory Information
The supplied material mentions PharmaCom Labs in connection with the product but does not provide a marketing authorisation number, EU authorisation, national licence or verified regulatory status.
Accordingly, no claim is made that PharmaMix-M 300 is EU-authorised, prescription-only across all European countries or legally saleable throughout the EU.
Manufacturer Information
Manufacturer mentioned in supplied source: PharmaCom Labs.
No additional manufacturing, GMP, batch-release or regulatory documentation was supplied.
Presentation
PharmaMix-M 300 – 300 mg/ml, 10 ml injectable preparation.
The supplied information describes the product as a drostanolone-based mixture but does not provide a complete ingredient-by-ingredient formulation.
Storage
No specific storage temperature was provided in the supplied source.
Follow the current manufacturer’s official storage instructions and packaging information.
Important Pharmaceutical Disclaimer
PharmaMix-M 300 is described in the supplied source as an anabolic/androgenic steroid mixture. The bodybuilding and performance-related claims in the source have been treated as marketing context rather than established medical benefits.
This product description is based only on the information supplied. It does not replace official prescribing information or professional medical advice, and it does not establish regulatory approval, clinical efficacy or a validated human treatment regimen.
